腎線維症治療の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Kidney Fibrosis Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D005-00558 • 出版社/出版日：GlobalInfoResearch / 2020年5月29日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール • 産業分類：医療・製薬

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、腎線維症治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。腎線維症治療の種類別市場規模（アンジオテンシン変換酵素（ACE）阻害剤、ピルフェニドン、レニン阻害剤、アンジオテンシンII受容体遮断薬（ARB）、バソペプチダーゼ阻害剤）、用途別市場規模（慢性腎疾患、腎がん治療、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Merck and Co(US)、BioLine Rx(Israel)、InterMune Inc(US)、Pfizer Inc(US)、ProMetic Life-Sciences Inc(Canada)、F. Hoffman-La Roche(Switzerland)、La Jolla Pharmaceutical Company(US)、Galectin Therapeutics(US)、Genzyme Corporation(US) ・地域別グローバル市場分析 2015年-2020年 ・腎線維症治療の北米市場（アメリカ、カナダ、メキシコ） ・腎線維症治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・腎線維症治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・腎線維症治療の南米市場（ブラジル、アルゼンチン） ・腎線維症治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：アンジオテンシン変換酵素（ACE）阻害剤、ピルフェニドン、レニン阻害剤、アンジオテンシンII受容体遮断薬（ARB）、バソペプチダーゼ阻害剤 ・用途別分析：慢性腎疾患、腎がん治療、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論

Market Overview
The global Kidney Fibrosis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Kidney Fibrosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Kidney Fibrosis Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Kidney Fibrosis Treatment market has been segmented into:
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors

By Application, Kidney Fibrosis Treatment has been segmented into:
Chronic Kidney Diseases
Kidney Cancer Treatment
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Kidney Fibrosis Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Kidney Fibrosis Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Kidney Fibrosis Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Kidney Fibrosis Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Kidney Fibrosis Treatment Market Share Analysis
Kidney Fibrosis Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Kidney Fibrosis Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Kidney Fibrosis Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Kidney Fibrosis Treatment are:
Merck and Co(US)
BioLine Rx(Israel)
InterMune Inc(US)
Pfizer Inc(US)
ProMetic Life-Sciences Inc(Canada)
F. Hoffman-La Roche(Switzerland)
La Jolla Pharmaceutical Company(US)
Galectin Therapeutics(US)
Genzyme Corporation(US)

レポート目次

---

Table of Contents

1 Kidney Fibrosis Treatment Market Overview
1.1 Product Overview and Scope of Kidney Fibrosis Treatment
1.2 Classification of Kidney Fibrosis Treatment by Type
1.2.1 Global Kidney Fibrosis Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Kidney Fibrosis Treatment Revenue Market Share by Type in 2019
1.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors
1.2.4 Pirfenidone
1.2.5 Renin Inhibitors
1.2.6 Angiotensin II Receptor Blockers (ARBs)
1.2.7 Vasopeptidase Inhibitors
1.3 Global Kidney Fibrosis Treatment Market by Application
1.3.1 Overview: Global Kidney Fibrosis Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Chronic Kidney Diseases
1.3.3 Kidney Cancer Treatment
1.3.4 Others
1.4 Global Kidney Fibrosis Treatment Market by Regions
1.4.1 Global Kidney Fibrosis Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Kidney Fibrosis Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Kidney Fibrosis Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Kidney Fibrosis Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Kidney Fibrosis Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Kidney Fibrosis Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Kidney Fibrosis Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Merck and Co(US)
2.1.1 Merck and Co(US) Details
2.1.2 Merck and Co(US) Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Merck and Co(US) SWOT Analysis
2.1.4 Merck and Co(US) Product and Services
2.1.5 Merck and Co(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 BioLine Rx(Israel)
2.2.1 BioLine Rx(Israel) Details
2.2.2 BioLine Rx(Israel) Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 BioLine Rx(Israel) SWOT Analysis
2.2.4 BioLine Rx(Israel) Product and Services
2.2.5 BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 InterMune Inc(US)
2.3.1 InterMune Inc(US) Details
2.3.2 InterMune Inc(US) Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 InterMune Inc(US) SWOT Analysis
2.3.4 InterMune Inc(US) Product and Services
2.3.5 InterMune Inc(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer Inc(US)
2.4.1 Pfizer Inc(US) Details
2.4.2 Pfizer Inc(US) Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer Inc(US) SWOT Analysis
2.4.4 Pfizer Inc(US) Product and Services
2.4.5 Pfizer Inc(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 ProMetic Life-Sciences Inc(Canada)
2.5.1 ProMetic Life-Sciences Inc(Canada) Details
2.5.2 ProMetic Life-Sciences Inc(Canada) Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 ProMetic Life-Sciences Inc(Canada) SWOT Analysis
2.5.4 ProMetic Life-Sciences Inc(Canada) Product and Services
2.5.5 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 F. Hoffman-La Roche(Switzerland)
2.6.1 F. Hoffman-La Roche(Switzerland) Details
2.6.2 F. Hoffman-La Roche(Switzerland) Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 F. Hoffman-La Roche(Switzerland) SWOT Analysis
2.6.4 F. Hoffman-La Roche(Switzerland) Product and Services
2.6.5 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 La Jolla Pharmaceutical Company(US)
2.7.1 La Jolla Pharmaceutical Company(US) Details
2.7.2 La Jolla Pharmaceutical Company(US) Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 La Jolla Pharmaceutical Company(US) SWOT Analysis
2.7.4 La Jolla Pharmaceutical Company(US) Product and Services
2.7.5 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Galectin Therapeutics(US)
2.8.1 Galectin Therapeutics(US) Details
2.8.2 Galectin Therapeutics(US) Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Galectin Therapeutics(US) SWOT Analysis
2.8.4 Galectin Therapeutics(US) Product and Services
2.8.5 Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Genzyme Corporation(US)
2.9.1 Genzyme Corporation(US) Details
2.9.2 Genzyme Corporation(US) Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Genzyme Corporation(US) SWOT Analysis
2.9.4 Genzyme Corporation(US) Product and Services
2.9.5 Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Kidney Fibrosis Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Kidney Fibrosis Treatment Players Market Share
3.2.2 Top 10 Kidney Fibrosis Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Kidney Fibrosis Treatment Revenue and Market Share by Regions
4.2 North America Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
5 North America Kidney Fibrosis Treatment Revenue by Countries
5.1 North America Kidney Fibrosis Treatment Revenue by Countries (2015-2020)
5.2 USA Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
6 Europe Kidney Fibrosis Treatment Revenue by Countries
6.1 Europe Kidney Fibrosis Treatment Revenue by Countries (2015-2020)
6.2 Germany Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
6.4 France Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Kidney Fibrosis Treatment Revenue by Countries
7.1 Asia-Pacific Kidney Fibrosis Treatment Revenue by Countries (2015-2020)
7.2 China Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
7.5 India Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
8 South America Kidney Fibrosis Treatment Revenue by Countries
8.1 South America Kidney Fibrosis Treatment Revenue by Countries (2015-2020)
8.2 Brazil Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Kidney Fibrosis Treatment by Countries
9.1 Middle East & Africa Kidney Fibrosis Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Kidney Fibrosis Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Kidney Fibrosis Treatment Market Forecast by Type (2019-2024)
10.3 Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2015-2025)
10.4 Pirfenidone Revenue Growth Rate (2015-2025)
10.5 Renin Inhibitors Revenue Growth Rate (2015-2025)
10.6 Angiotensin II Receptor Blockers (ARBs) Revenue Growth Rate (2015-2025)
10.7 Vasopeptidase Inhibitors Revenue Growth Rate (2015-2025)
11 Global Kidney Fibrosis Treatment Market Segment by Application
11.1 Global Kidney Fibrosis Treatment Revenue Market Share by Application (2015-2020)
11.2 Kidney Fibrosis Treatment Market Forecast by Application (2019-2024)
11.3 Chronic Kidney Diseases Revenue Growth (2015-2020)
11.4 Kidney Cancer Treatment Revenue Growth (2015-2020)
11.5 Others Revenue Growth (2015-2020)
12 Global Kidney Fibrosis Treatment Market Size Forecast (2021-2025)
12.1 Global Kidney Fibrosis Treatment Market Size Forecast (2021-2025)
12.2 Global Kidney Fibrosis Treatment Market Forecast by Regions (2021-2025)
12.3 North America Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
12.6 South America Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Kidney Fibrosis Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Kidney Fibrosis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Kidney Fibrosis Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Kidney Fibrosis Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Merck and Co(US) Corporate Information, Location and Competitors
Table 6. Merck and Co(US) Kidney Fibrosis Treatment Major Business
Table 7. Merck and Co(US) Kidney Fibrosis Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Merck and Co(US) SWOT Analysis
Table 9. Merck and Co(US) Kidney Fibrosis Treatment Product and Solutions
Table 10. Merck and Co(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. BioLine Rx(Israel) Corporate Information, Location and Competitors
Table 12. BioLine Rx(Israel) Kidney Fibrosis Treatment Major Business
Table 13. BioLine Rx(Israel) Kidney Fibrosis Treatment Total Revenue (USD Million) (2018-2019)
Table 14. BioLine Rx(Israel) SWOT Analysis
Table 15. BioLine Rx(Israel) Kidney Fibrosis Treatment Product and Solutions
Table 16. BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. InterMune Inc(US) Corporate Information, Location and Competitors
Table 18. InterMune Inc(US) Kidney Fibrosis Treatment Major Business
Table 19. InterMune Inc(US) Kidney Fibrosis Treatment Total Revenue (USD Million) (2017-2018)
Table 20. InterMune Inc(US) SWOT Analysis
Table 21. InterMune Inc(US) Kidney Fibrosis Treatment Product and Solutions
Table 22. InterMune Inc(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Pfizer Inc(US) Corporate Information, Location and Competitors
Table 24. Pfizer Inc(US) Kidney Fibrosis Treatment Major Business
Table 25. Pfizer Inc(US) Kidney Fibrosis Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Pfizer Inc(US) SWOT Analysis
Table 27. Pfizer Inc(US) Kidney Fibrosis Treatment Product and Solutions
Table 28. Pfizer Inc(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. ProMetic Life-Sciences Inc(Canada) Corporate Information, Location and Competitors
Table 30. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Major Business
Table 31. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Total Revenue (USD Million) (2017-2018)
Table 32. ProMetic Life-Sciences Inc(Canada) SWOT Analysis
Table 33. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Product and Solutions
Table 34. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. F. Hoffman-La Roche(Switzerland) Corporate Information, Location and Competitors
Table 36. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Major Business
Table 37. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Total Revenue (USD Million) (2017-2018)
Table 38. F. Hoffman-La Roche(Switzerland) SWOT Analysis
Table 39. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Product and Solutions
Table 40. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. La Jolla Pharmaceutical Company(US) Corporate Information, Location and Competitors
Table 42. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Major Business
Table 43. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Total Revenue (USD Million) (2017-2018)
Table 44. La Jolla Pharmaceutical Company(US) SWOT Analysis
Table 45. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Product and Solutions
Table 46. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Galectin Therapeutics(US) Corporate Information, Location and Competitors
Table 48. Galectin Therapeutics(US) Kidney Fibrosis Treatment Major Business
Table 49. Galectin Therapeutics(US) Kidney Fibrosis Treatment Total Revenue (USD Million) (2017-2018)
Table 50. Galectin Therapeutics(US) SWOT Analysis
Table 51. Galectin Therapeutics(US) Kidney Fibrosis Treatment Product and Solutions
Table 52. Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Genzyme Corporation(US) Corporate Information, Location and Competitors
Table 54. Genzyme Corporation(US) Kidney Fibrosis Treatment Major Business
Table 55. Genzyme Corporation(US) Kidney Fibrosis Treatment Total Revenue (USD Million) (2017-2018)
Table 56. Genzyme Corporation(US) SWOT Analysis
Table 57. Genzyme Corporation(US) Kidney Fibrosis Treatment Product and Solutions
Table 58. Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Global Kidney Fibrosis Treatment Revenue (Million USD) by Players (2015-2020)
Table 60. Global Kidney Fibrosis Treatment Revenue Share by Players (2015-2020)
Table 61. Global Kidney Fibrosis Treatment Revenue (Million USD) by Regions (2015-2020)
Table 62. Global Kidney Fibrosis Treatment Revenue Market Share by Regions (2015-2020)
Table 63. North America Kidney Fibrosis Treatment Revenue by Countries (2015-2020)
Table 64. North America Kidney Fibrosis Treatment Revenue Market Share by Countries (2015-2020)
Table 65. Europe Kidney Fibrosis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 66. Asia-Pacific Kidney Fibrosis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 67. South America Kidney Fibrosis Treatment Revenue by Countries (2015-2020)
Table 68. South America Kidney Fibrosis Treatment Revenue Market Share by Countries (2015-2020)
Table 69. Middle East and Africa Kidney Fibrosis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 70. Middle East and Africa Kidney Fibrosis Treatment Revenue Market Share by Countries (2015-2020)
Table 71. Global Kidney Fibrosis Treatment Revenue (Million USD) by Type (2015-2020)
Table 72. Global Kidney Fibrosis Treatment Revenue Share by Type (2015-2020)
Table 73. Global Kidney Fibrosis Treatment Revenue Forecast by Type (2021-2025)
Table 74. Global Kidney Fibrosis Treatment Revenue by Application (2015-2020)
Table 75. Global Kidney Fibrosis Treatment Revenue Share by Application (2015-2020)
Table 76. Global Kidney Fibrosis Treatment Revenue Forecast by Application (2021-2025)
Table 77. Global Kidney Fibrosis Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Kidney Fibrosis Treatment Picture
Figure 2. Global Kidney Fibrosis Treatment Revenue Market Share by Type in 2019
Figure 3. Angiotensin Converting Enzyme (ACE) Inhibitors Picture
Figure 4. Pirfenidone Picture
Figure 5. Renin Inhibitors Picture
Figure 6. Angiotensin II Receptor Blockers (ARBs) Picture
Figure 7. Vasopeptidase Inhibitors Picture
Figure 8. Kidney Fibrosis Treatment Revenue Market Share by Application in 2019
Figure 9. Chronic Kidney Diseases Picture
Figure 10. Kidney Cancer Treatment Picture
Figure 11. Others Picture
Figure 12. Global Kidney Fibrosis Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Kidney Fibrosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Kidney Fibrosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Kidney Fibrosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Kidney Fibrosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Kidney Fibrosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Kidney Fibrosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Kidney Fibrosis Treatment Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Kidney Fibrosis Treatment Revenue Market Share in 2019
Figure 21. Global Top 10 Players Kidney Fibrosis Treatment Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Kidney Fibrosis Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Kidney Fibrosis Treatment Revenue Market Share by Regions (2015-2020)
Figure 25. Global Kidney Fibrosis Treatment Revenue Market Share by Regions in 2018
Figure 26. North America Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Europe Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 29. South America Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 31. North America Kidney Fibrosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 32. North America Kidney Fibrosis Treatment Revenue Market Share by Countries in 2019
Figure 33. USA Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Canada Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 36. Europe Kidney Fibrosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Kidney Fibrosis Treatment Revenue Market Share by Countries in 2019
Figure 38. Germany Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 39. UK Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 40. France Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Russia Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Italy Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Kidney Fibrosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Kidney Fibrosis Treatment Revenue Market Share by Countries in 2019
Figure 45. China Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Japan Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Korea Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 48. India Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 50. South America Kidney Fibrosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 51. South America Kidney Fibrosis Treatment Revenue Market Share by Countries in 2019
Figure 52. Brazil Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Kidney Fibrosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Kidney Fibrosis Treatment Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 57. UAE Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Kidney Fibrosis Treatment Revenue and Growth Rate (2015-2020)
Figure 60. Global Kidney Fibrosis Treatment Revenue Share by Type (2015-2020)
Figure 61. Global Kidney Fibrosis Treatment Revenue Share by Type in 2019
Figure 62. Global Kidney Fibrosis Treatment Market Share Forecast by Type (2021-2025)
Figure 63. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate (2015-2020)
Figure 64. Global Pirfenidone Revenue Growth Rate (2015-2020)
Figure 65. Global Renin Inhibitors Revenue Growth Rate (2015-2020)
Figure 66. Global Angiotensin II Receptor Blockers (ARBs) Revenue Growth Rate (2015-2020)
Figure 67. Global Vasopeptidase Inhibitors Revenue Growth Rate (2015-2020)
Figure 68. Global Kidney Fibrosis Treatment Revenue Share by Application (2015-2020)
Figure 69. Global Kidney Fibrosis Treatment Revenue Share by Application in 2019
Figure 70. Global Kidney Fibrosis Treatment Market Share Forecast by Application (2021-2025)
Figure 71. Global Chronic Kidney Diseases Revenue Growth Rate (2015-2020)
Figure 72. Global Kidney Cancer Treatment Revenue Growth Rate (2015-2020)
Figure 73. Global Others Revenue Growth Rate (2015-2020)
Figure 74. Global Kidney Fibrosis Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Kidney Fibrosis Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Kidney Fibrosis Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
Figure 78. Europe Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
Figure 80. South America Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Kidney Fibrosis Treatment Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel

---